August 13, 2002
Studies suggest that drug treatment and syringe exchange programs play a role in reducing HCV infection among participants by promoting drug abstinence or safer injection practices among those who continue to use drugs. The New York City Department of Health conducted a survey of local drug treatment and syringe exchange programs to determine whether their HCV screening and counseling practices were carried out, as recommended in recent federal guidelines.
In March 1999, 141 agency directors (all 132 drug treatment programs listed in the state drug services directory, nine syringe exchange programs and eight unaffiliated drug treatment programs) received a survey asking about client characteristics, hepatitis screening (based on laboratory testing or client self-report), HCV education and counseling and barriers to offering HCV services. Seventy percent of the programs (99) and four syringe exchange programs responded. The analysis of data was based on 113 questionnaires completed by 109 programs and the four syringe exchange programs.
Findings from the study included the following:
This survey, among others, found that despite enrollment in treatment programs, many clients continue to use illicit drugs and engage in practices that place them at risk for HCV infection. Because drug treatment programs and syringe exchange programs provide access to the highest-risk population for HCV, targeted screening at these facilities would prove to be cost-effective, especially among younger clients who may have the highest incidence of HCV. Facilities should be provided with adequate resources to initiate and expand their HCV screening and education programs, the authors concluded.
American Journal of Public Health
08.02; Vol. 92; No. 8:1254-1256; Chi-Chi N. Udeagu Pratt, M.P.H.; Denise Paone, Ed.D.; Rosalind J. Carter, Ph.D.; Marcelle C. Layton, M.D.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Two-Drug HIV Treatment Regimens Effective in Latest Studies|
|The Need to Advocate for Fair HIV Drug Prices|
|'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?|
|IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV|
|Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity|